基石藥業(02616.HK)聯合療法獲臨床試驗批准
基石藥業(02616.HK)公布,公司治療局部晚期或轉移性肝細胞癌的CS1001聯合BLU-554療法在中國獲臨床試驗批准。試驗旨在評價此聯合療法在晚期肝細胞癌中的安全性、耐受性、藥代動力學及藥效學特徵和抗腫瘤療效。
CS1001是基石藥業自主研發的抗PD-L1單抗,也是公司三款腫瘤免疫治療骨幹產品之一。BLU-554則由公司合作夥伴Blueprint開發,是一款強效高選擇性的成纖維細胞生長因數受體-4抑制劑。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.